Norhan Mohammed, M.D., Ph.D., M.Sc.

Postdoctoral Research Associate

Department of Translational Medicine; Translational Glycobiology Institute at FIU

Office: AHC5- 458

Phone: 305-348-8105


Specialty: Translational Medicine, Cancer Glycobiology

Languages spoken: English, Arabic

Areas of Interest: Cancer Biology, Immunology, Glycobiology

Dr. Norhan Mohammed is a Postdoctoral Associate in the Translational Glycobiology Institute at HWCOM. Her research focuses on understanding how glycome-related molecules contribute to cancer metastasis. She aims to develop a novel biomarker capable of early detection of melanoma and discover new targets for melanoma therapy.

Dr. Mohammed has recently received her Ph.D. degree in Biochemistry with Summa Cum Laude honors from FIU, under the mentorship of Dr. Charles Dimitroff. Prior to joining FIU, Dr. Mohammed obtained her M.D. from Assiut University, Egypt, and subsequently worked as a resident physician in the Tropical Medicine and Gastroenterology Department at Assiut University Hospital. She later completed her Master’s degree in Medical Biochemistry from South Valley University, Egypt, where she served as an instructor of biochemistry for medical students.


Ph.D. in Biochemistry, Florida International University, 2023
M.Sc. in Medical Biochemistry, South Valley University, Egypt, 2017
M.D., Assiut University, Egypt, 2012


  • The Ralph J. Bernacki Translational Glycobiology Research Scholar Award, 2023
  • FIU Dissertation Year Fellowship, 2023
  • Sigma XI Grants in Aid of Research (GIAR) Award, 2022
  • Society for Glycobiology Travel Award, 2021
  • Graduate Student Government Travel Award, Egypt, 2018
  • South Valley University Award for Scientific Publication, Egypt, 2018
  • Assiut University Award for Excellent Academic Performance, Egypt, 2004 - 2010

Selected Publications

  1. Mohammed NB, Antonopoulos A, Dell A, Haslam SM, Dimitroff CJ. The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. Advances in Cancer Research, 2023 Jan (Vol. 157, pp. 157-193).
  2. Lau LS, Mohammed NB, Dimitroff CJ. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and-9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy. International Journal of Molecular Sciences, 2022 Dec 8;23(24):15554.
  3. Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NB, Wells M, Staudinger C, Griswold A, Chandler KB. Hypoxia Controls the Glycome Signature and Galectin-8–Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma. Journal of investigative dermatology, 2023 Mar 1;143(3):456-69.
  4. Mohammed Z, Saleh Y, AbdelSalam EM, Mohammed NB, El-Bana E, Hirshon JM. Evaluation of the Revised Trauma Score, MGAP, and GAP scoring systems in predicting mortality of adult trauma patients in a low-resource setting. BMC Emergency Medicine, 2022 May;22(1):1-0.
  5. Chakraborty A, Mohammed NB, Bernasconi AE, Dimitroff CJ. Analysis of Galectin-Binding Receptors on B Cells. Methods in Molecular Biology, 2022 Mar (pp. 565-580). New York, NY: Springer US.
  6. Perez M, Chakraborty A, Lau LS, Mohammed NB, Dimitroff CJ. Melanoma‐associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target. British Journal of Dermatology, 2021 Aug;185(2):294-301